期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

靶向表皮生长因子受体的肿瘤生物治疗方法研究进展 被引量：17

Epidermal growth factor receptor-targeted tumor biotherapies:an advance
下载PDF
导出
摘要 肿瘤生物治疗(cancer biotherapy)已经成为继手术、放疗和化疗三大经典肿瘤治疗模式后的第四模式。在肿瘤生物治疗中,表皮生长因子受体(epidermal growth factor receptor,EGFR)靶点扮演着重要角色。EGFR为一种相对分子质量为170 000的酪氨酸蛋白激酶型受体,在多种恶性肿瘤存在过表达,在肿瘤发生、发展中起着重要作用。靶向EGFR的肿瘤生物治疗方法主要包括:基因沉默治疗、显性负性治疗、单克隆抗体(monoclonal antibody,McAb)治疗、生物"导弹"治疗、EGFR酪氨酸激酶抑制剂(EGFR tyrosine kinase inhibitor,EGFR TKI)治疗、双特异性抗体(bispecific antibody,BsAb)治疗方法等。目前靶向EGFR的肿瘤生物治疗研究已经取得较大进展,随着研究的进一步深入,肿瘤的治疗必将跨入一个全新的时代。
作者 廖刚 王子卫
机构地区 重庆医科大学附属第一医院胃肠外科
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2009年第1期97-100,共4页 Chinese Journal of Cancer Biotherapy
关键词 表皮生长因子受体 肿瘤生物治疗 显性负性突变体 酪氨酸激酶抑制剂 单克隆抗体
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1Yarden Y. The EGFR family and its ligands in human cancer, signalling mechanisms and therapeutic opportunities [J].Eur J Cancer, 2001, 37 (Suppl 4) : S3-S8.
  • 2Mimori K, Nagahara H, Sudo T, et al. The epidermal growth factor receptor gene sequence is highly conserved in primarygastric cancers [J]. J Surg Oncol, 2006, 93(1) : 44-46.
  • 3Dhar A, Mehta S, Banerjee S, et al. Epidermal growth factor repeptor: is a novel therapeutic target for pancreatic cancer [J]? Front Biosci, 2005, 10 : 1763-1767.
  • 4Chan JK, Pham H, You X J, et al. Suppression of ovarian cancer cell tumorigenicity and evasion of cisplatin resistance using a truncated epidermal growth factor reeeptor in a rat model [J].Cancer Res, 2005, 65 ( 8 ) : 3243-3248.
  • 5Wu X, Deng Y, Wang G, et al. Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells [ J ]. J Surg Res, 2007, 138(1) : 56-63.
  • 6Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic coloreetal cancer [J]. N Engl J Med, 2004, 351 (4) : 337- 345.
  • 7Thienelt CD, Bunn PA Jr, Hanna N, et al. Muhicenter phase I / II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer [ J]. J Clin Oncol, 2005, 23 (34) : 8786-8793.
  • 8Fukuoka M, Yano S, Giaeeone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer ( The IDEAL 1 Trial) [corrected] [J]. J Clin Oncol, 2003, 21(12): 2237-2246.
  • 9Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial [J]. JAMA, 2003, 290(16) : 2149-2158.
  • 10Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non- small-cell lung cancer to gefitinib [J]. N Engl J Med, 2004, 350 (21) : 2129-2139.

二级参考文献35

  • 1Lam TH,Leung PY,Foo W,et al.Report of cancer expert working group on cancer prevention and screening[R].Hong Kong,2004.
  • 2Schwartz AG,Prysak GM,Bock CH,et al.The molecular epidemiology of lung cancer[J].Carcionogenesis,2007,28(3):507-518.
  • 3Stewart BW,Kleihues P.World cancer report[R].Geneva:International agency for research on cancer,2003.
  • 4Toh CK,Gao F,Lim WT,et al.Never-smokers with lung cancer:Epidemiologic evidence of a distinct disease entity[J].J Clin Oncol 2006,24(15):2245-2251.
  • 5WHO.World cancer report provides clear evidence that action on smoking,diet and infections can prevent one third of cancers,another third can be cured[R].Geneva:WHO Media Centre Press Release,2003.
  • 6Yu IT,Chiu YL,Au JS,et al.Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women[J].Cancer Res,2006,66(9):4691-4697.
  • 7Raben D,Helfrich B,Bunn PA Jr.Targeted therapies for non-small-cell lung cancer:Biology,rationale,and preclinical results from a radiation oncology perspective[J].Int J Radiat Oncol Biol Phys,2004,59(2 Suppl 1):S27-S38.
  • 8Ono M,Kuwano M.Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs[J].Clin Cancer Res,2006,12(24):7242-7251.
  • 9Rosell R,Taron M,Reguart N,et al.Epidermal growth factor receptor activation:How exon 19 and 21 mutations changed our understanding of the pathway[J].Clin Cancer Res,2006,12(24):7222-7231.
  • 10Shepherd FA,Rodrigues PJ,Ciuleanu T,et al.Erlotinib in previously treated non-small-cell lung cancer[J].N Engl J Med,2005,353(2):123-132.

共引文献14

同被引文献138

引证文献17

二级引证文献32

中国肿瘤生物治疗杂志
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部